UiPath (NYSE:PATH) Trading 0.3% Higher

UiPath Inc. (NYSE:PATH - Get Free Report)'s stock price shot up 0.3% on Wednesday . The stock traded as high as $19.20 and last traded at $19.02. 1,062,177 shares were traded during trading, a decline of 88% from the average session volume of 8,521,017 shares. The stock had previously closed at $18.97.

Wall Street Analyst Weigh In

Several research firms have weighed in on PATH. Morgan Stanley boosted their target price on shares of UiPath from $17.00 to $25.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 14th. KeyCorp began coverage on shares of UiPath in a research report on Monday, April 8th. They set an "overweight" rating and a $27.00 target price on the stock. Scotiabank boosted their target price on shares of UiPath from $29.00 to $30.00 and gave the stock a "sector perform" rating in a research report on Thursday, March 14th. Evercore ISI boosted their target price on shares of UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research report on Thursday, March 14th. Finally, Truist Financial reissued a "buy" rating and set a $32.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $27.41.

UiPath Stock Performance

The firm's 50 day moving average is $21.99 and its 200-day moving average is $21.66. The stock has a market capitalization of $10.95 billion, a price-to-earnings ratio of -113.17 and a beta of 0.96.

UiPath (NYSE:PATH - Get Free Report) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $405.25 million during the quarter, compared to analysts' expectations of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. As a group, sell-side analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 16,000 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares of the company's stock, valued at $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 72,000 shares of company stock worth $1,591,360. Company insiders own 31.03% of the company's stock.

Institutional Investors Weigh In On UiPath

Large investors have recently modified their holdings of the business. Janney Montgomery Scott LLC grew its holdings in shares of UiPath by 27.2% in the first quarter. Janney Montgomery Scott LLC now owns 89,340 shares of the healthcare company's stock valued at $2,025,000 after purchasing an additional 19,126 shares during the period. Smith Group Asset Management LLC purchased a new stake in shares of UiPath in the first quarter valued at about $204,000. Private Advisor Group LLC grew its holdings in shares of UiPath by 90.0% in the first quarter. Private Advisor Group LLC now owns 70,293 shares of the healthcare company's stock valued at $1,594,000 after purchasing an additional 33,306 shares during the period. Warther Private Wealth LLC purchased a new stake in shares of UiPath in the first quarter valued at about $5,418,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of UiPath by 819.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 19,209 shares of the healthcare company's stock valued at $435,000 after purchasing an additional 17,120 shares during the period. Hedge funds and other institutional investors own 62.50% of the company's stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.